Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients

B. Braun

Status

Withdrawn

Conditions

Diabetic Complications

Treatments

Device: Saline

Device: Prontosan

Study type

Interventional

Funder types

Industry

Identifiers

NCT01554644

OPM-I-H-0910

Details and patient eligibility

About

This is a randomized controlled double blinded study involving two (2) investigational sites in the United States. All subjects (n=40) will receive either Prontosan Wound Irrigation Solution and Gel treatment or standard of care treatment (0.9% saline) and placebo gel. This is a 12-week study.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female diabetic (type I or II) patients ≥ 18 years of age.
Diabetic ulcer(s) present for ≥ 4 weeks located below the knee.
A total surface area of ≥ 3 cm2 and ≤ 16 cm2.
Willingness to wear an off-loading device if medically indicated (e.g., DH shoe or Walker).

Exclusion criteria

Pregnant women and nursing mothers.
Uncontrolled diabetes as defined by glucose levels >225 mg/dl.
HbA1c ≥ 12%.
Subjects with a wound infection.
Subjects receiving antibiotic therapy within 14 days of enrollment.
Subject with history of or clinical evidence of: Cardiac insufficiency (NYHA functional classification IV), angina pectoris (CCS functional classification IV), unstable pulmonary, renal, hepatic, endocrine or hematologic disease as determined by the Investigator (serum creatinine of > 3.0; transaminase or alkaline phosphatase levels equal to or greater than 5 times the upper limit) malnutrition (albumin < 2.5 g/dL).
Peripheral arterial occlusive disease with a non-palpable pulse on both dorsal pedial and the posterior tibial artery.
Presence of gangrene.
Active rheumatic or collagen vascular disease (including rheumatoid arthritis, scleroderma, and systemic lupus erythematosus)
Subjects that have been diagnosed with HBV, HVC, AIDS or are HIV positive.
Osteomyelitis diagnosed by x-ray, bone biopsy, or other radiological procedure within 90 days prior to Screening Period.
Active radiation therapy below the hip.
Subject currently receiving, or has received oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents within 30 days prior to Baseline Visit (Visit 1, Week 0) or is anticipated to require such agents during the course of the study.
Current participation or participation in another investigational drug or medical device study within the last 30 days.
Subjects who test positive for alcohol and or illicit drug use.
Subjects who are unable to comprehend or comply with study requirements or ability to sign an informed consent.
Subjects, who in the opinion of the Investigator would not be a suitable candidate for this study (reason for exclusion needs to be documented).